NCT00826241: A reported trial by National Institutes of Health Clinical Center (CC)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT00826241 |
|---|---|
| Title | A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 31, 2009 |
| Completion date | July 31, 2018 |
| Required reporting date | July 31, 2019, midnight |
| Actual reporting date | Feb. 4, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |